532 related articles for article (PubMed ID: 19818352)
21. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
22. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
[TBL] [Abstract][Full Text] [Related]
24. [Effects of acute and chronic murine cytomegalovirus infections on the ratio of regulatory T cells and expression of Th1/Th2 transcription factors T-bet/GATA-3].
Li YN; Zhou YF; Shu SN; Zhu DD; Yang ZF; Fang F
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2999-3002. PubMed ID: 19080080
[TBL] [Abstract][Full Text] [Related]
25. CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis.
Milani M; Ostlie N; Wu H; Wang W; Conti-Fine BM
J Neuroimmunol; 2006 Oct; 179(1-2):152-62. PubMed ID: 16945426
[TBL] [Abstract][Full Text] [Related]
26. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta.
Kong QF; Sun B; Bai SS; Zhai DX; Wang GY; Liu YM; Zhang SJ; Li R; Zhao W; Sun YY; Li N; Wang Q; Peng HS; Jin LH; Li HL
J Neuroimmunol; 2009 Feb; 207(1-2):83-91. PubMed ID: 19174310
[TBL] [Abstract][Full Text] [Related]
27. T-bet inhibits the in vivo differentiation of parasite-specific CD4+ Th17 cells in a T cell-intrinsic manner.
Guo S; Cobb D; Smeltz RB
J Immunol; 2009 May; 182(10):6179-86. PubMed ID: 19414771
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.
Pierau M; Engelmann S; Reinhold D; Lapp T; Schraven B; Bommhardt UH
J Immunol; 2009 Nov; 183(10):6124-34. PubMed ID: 19841181
[TBL] [Abstract][Full Text] [Related]
29. [The mechanism of prophylactic effects of nasal tolerance with a dual analogue on experimental autoimmune myasthenia gravis in young mice].
Liu SL; Huang Z
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):191-4. PubMed ID: 18433545
[TBL] [Abstract][Full Text] [Related]
30. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
31. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
32. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.
Schaffert H; Pelz A; Saxena A; Losen M; Meisel A; Thiel A; Kohler S
Eur J Immunol; 2015 May; 45(5):1339-47. PubMed ID: 25676041
[TBL] [Abstract][Full Text] [Related]
33. Tat-mediated intracellular delivery of T-bet protein into THP-1 cells can induce Th1-type response.
Yang M; Wang S; Wang S; Ma J; Xu X; Mao C; Ma B; Tong J; Qiu G; Shao Q; Ding Q; Xu H
Immunol Invest; 2008; 37(2):97-111. PubMed ID: 18300036
[TBL] [Abstract][Full Text] [Related]
34. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
[TBL] [Abstract][Full Text] [Related]
35. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
36. T-cell-specific deletion of gp130 renders the highly susceptible IL-10-deficient mouse resistant to intestinal nematode infection.
Fasnacht N; Greweling MC; Bollati-Fogolín M; Schippers A; Müller W
Eur J Immunol; 2009 Aug; 39(8):2173-83. PubMed ID: 19593768
[TBL] [Abstract][Full Text] [Related]
37. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
38. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO.
Kong QF; Sun B; Wang GY; Zhai DX; Mu LL; Wang DD; Wang JH; Li R; Li HL
Eur J Immunol; 2009 Mar; 39(3):800-9. PubMed ID: 19283707
[TBL] [Abstract][Full Text] [Related]
39. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12.
Schulz EG; Mariani L; Radbruch A; Höfer T
Immunity; 2009 May; 30(5):673-83. PubMed ID: 19409816
[TBL] [Abstract][Full Text] [Related]
40. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
